BMS expands Krazati’s FDA label to include colorectal cancer
Pharmaceutical Technology
JUNE 24, 2024
The KRAS inhibitor, Krazati, is expected to generate $1.3bn in global sales in 2029, as per GlobalData’s analysis.
2029 FDA Labelling 
52 
Lilly’s Olumiant okayed in alopecia, with Pfizer, Concert in hot pursuit
pharmaphorum
JUNE 14, 2022
Eli Lilly and Incyte’s Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,000 people in the US. Olumiant is also approved to treat rheumatoid arthritis and some hospitalised patients with COVID-19, and made more than $1.1
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3
pharmaphorum
OCTOBER 26, 2022
The first patient has already been enrolled into its FIBRONEER phase 3 programme for BI 1015550, which already has a breakthrough designation from the FDA after a positive phase 2 trial showed improved lung function in patients with IPF over a 12-week period.
Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023
Pharmaceutical Technology
APRIL 28, 2023
FDA approval follows the successful outcomes of the Sustain Forte trial (NCT03989232), the results of which displayed a superior reduction in HbA1c levels with once-weekly semaglutide 2.0mg, in comparison to once-weekly semaglutide 1.0mg, among individuals suffering from type 2 diabetes.
CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program
The FDA Law Blog
DECEMBER 3, 2023
The manufacturer’s agreement must cover all its labeler codes that contain an applicable drug or a selected drug. All labeler codes that are covered by Discount Program agreements will be distributed to PDP sponsors and posted on the CMS website. had Part D expenditures on or before August 16, 2022).
AbbVie files Vraylar as add-on therapy for depression in US
pharmaphorum
FEBRUARY 23, 2022
AbbVie has filed with the FDA to extend the uses of its bipolar disorder therapy Vraylar to include adjunctive therapy for major depressive disorder, part of a plan to build sales of the drug to peak sales of $4 billion or more. Analysts at GlobalData are predicting peak sales of $383 million for the drug in 2029.
T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies
Pharmaceutical Technology
JANUARY 10, 2023
billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. Specifically, across all the major classes there are significant developments, label updates, and biosimilar launches that are driving their growth. billion in 2029, although its sales growth is likely to continue beyond 2029.
Let's personalize your content